Dosimetric analysis of the short-ranged particle emitter161 tb for radionuclide therapy of metastatic prostate cancer

Peter Bernhardt; Johanna Svensson; Jens Hemmingsson; Nicholas P. van der Meulen; Jan Rijn Zeevaart; Mark W. Konijnenberg; Cristina Müller; Jon Kindblom

doi:10.3390/cancers13092011

Dosimetric analysis of the short-ranged particle emitter¹⁶¹ tb for radionuclide therapy of metastatic prostate cancer

Peter Bernhardt^*, Johanna Svensson, Jens Hemmingsson, Nicholas P. van der Meulen, Jan Rijn Zeevaart, Mark W. Konijnenberg, Cristina Müller, Jon Kindblom

^*Corresponding author for this work

Radiology & Nuclear Medicine

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

5 Downloads (Pure)

Abstract

The aim of this study was to analyze the required absorbed doses to detectable metastases (D_req ) when using radionuclides with prostate specific membrane antigen (PSMA)-targeting radioligands to achieve a high probability for metastatic control. The Monte Carlo based analysis was performed for the clinically-used radionuclides yttrium-90, iodine-131, lutetium-177, and actinium-225, and the newly-proposed low-energy electron emitter terbium-161. It was demonstrated that metastatic formation rate highly influenced the metastatic distribution. Lower values generated few large detectable metastases, as in the case with oligo metastases, while high values generated a distribution of multiple small detectable metastases, as observed in patients with diffused visualized metastases. With equal number of detectable metastases, the total metastatic volume burden was 4–6 times higher in the oligo metastatic scenario compared to the diffusely visualized scenario. The D_req was around 30% higher for the situations with 20 detectable metastases compared to one detectable metastasis. The D_req for iodine-131 and yttrium-90 was high (920–3300 Gy). The D_req for lutetium-177 was between 560 and 780 Gy and considerably lower D_req were obtained for actinium-225 and terbium-161, with 240–330 Gy and 210–280 Gy, respectively. In conclusion, the simulations demonstrated that terbium-161 has the potential for being a more effective targeted radionuclide therapy for metastases using PSMA ligands.

Original language	English
Article number	2011
Journal	Cancers
Volume	13
Issue number	9
DOIs	https://doi.org/10.3390/cancers13092011
Publication status	Published - 22 Apr 2021

Bibliographical note

Funding: This work was supported by the Swedish Cancer Society, the King Gustav V Jubilee Clinic Cancer Research Foundation, the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement, the Swedish Research Council, the Swiss National Science Foundation (IZLIZ3_156800), and the NET Research Foundation Petersen Investigator Award 2018.

Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers13092011

cancers-13-02011-v3Licence: CC BY

Cite this

@article{c8457907db1e4be1bcdd157d0c9afb94,

title = "Dosimetric analysis of the short-ranged particle emitter161 tb for radionuclide therapy of metastatic prostate cancer",

abstract = "The aim of this study was to analyze the required absorbed doses to detectable metastases (Dreq ) when using radionuclides with prostate specific membrane antigen (PSMA)-targeting radioligands to achieve a high probability for metastatic control. The Monte Carlo based analysis was performed for the clinically-used radionuclides yttrium-90, iodine-131, lutetium-177, and actinium-225, and the newly-proposed low-energy electron emitter terbium-161. It was demonstrated that metastatic formation rate highly influenced the metastatic distribution. Lower values generated few large detectable metastases, as in the case with oligo metastases, while high values generated a distribution of multiple small detectable metastases, as observed in patients with diffused visualized metastases. With equal number of detectable metastases, the total metastatic volume burden was 4–6 times higher in the oligo metastatic scenario compared to the diffusely visualized scenario. The Dreq was around 30% higher for the situations with 20 detectable metastases compared to one detectable metastasis. The Dreq for iodine-131 and yttrium-90 was high (920–3300 Gy). The Dreq for lutetium-177 was between 560 and 780 Gy and considerably lower Dreq were obtained for actinium-225 and terbium-161, with 240–330 Gy and 210–280 Gy, respectively. In conclusion, the simulations demonstrated that terbium-161 has the potential for being a more effective targeted radionuclide therapy for metastases using PSMA ligands.",

author = "Peter Bernhardt and Johanna Svensson and Jens Hemmingsson and {van der Meulen}, {Nicholas P.} and Zeevaart, {Jan Rijn} and Konijnenberg, {Mark W.} and Cristina M{\"u}ller and Jon Kindblom",

note = "Funding: This work was supported by the Swedish Cancer Society, the King Gustav V Jubilee Clinic Cancer Research Foundation, the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement, the Swedish Research Council, the Swiss National Science Foundation (IZLIZ3_156800), and the NET Research Foundation Petersen Investigator Award 2018. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = apr,

day = "22",

doi = "10.3390/cancers13092011",

language = "English",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "9",

}

TY - JOUR

T1 - Dosimetric analysis of the short-ranged particle emitter161 tb for radionuclide therapy of metastatic prostate cancer

AU - Bernhardt, Peter

AU - Svensson, Johanna

AU - Hemmingsson, Jens

AU - van der Meulen, Nicholas P.

AU - Zeevaart, Jan Rijn

AU - Konijnenberg, Mark W.

AU - Müller, Cristina

AU - Kindblom, Jon

N1 - Funding: This work was supported by the Swedish Cancer Society, the King Gustav V Jubilee Clinic Cancer Research Foundation, the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement, the Swedish Research Council, the Swiss National Science Foundation (IZLIZ3_156800), and the NET Research Foundation Petersen Investigator Award 2018. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/4/22

Y1 - 2021/4/22

N2 - The aim of this study was to analyze the required absorbed doses to detectable metastases (Dreq ) when using radionuclides with prostate specific membrane antigen (PSMA)-targeting radioligands to achieve a high probability for metastatic control. The Monte Carlo based analysis was performed for the clinically-used radionuclides yttrium-90, iodine-131, lutetium-177, and actinium-225, and the newly-proposed low-energy electron emitter terbium-161. It was demonstrated that metastatic formation rate highly influenced the metastatic distribution. Lower values generated few large detectable metastases, as in the case with oligo metastases, while high values generated a distribution of multiple small detectable metastases, as observed in patients with diffused visualized metastases. With equal number of detectable metastases, the total metastatic volume burden was 4–6 times higher in the oligo metastatic scenario compared to the diffusely visualized scenario. The Dreq was around 30% higher for the situations with 20 detectable metastases compared to one detectable metastasis. The Dreq for iodine-131 and yttrium-90 was high (920–3300 Gy). The Dreq for lutetium-177 was between 560 and 780 Gy and considerably lower Dreq were obtained for actinium-225 and terbium-161, with 240–330 Gy and 210–280 Gy, respectively. In conclusion, the simulations demonstrated that terbium-161 has the potential for being a more effective targeted radionuclide therapy for metastases using PSMA ligands.

AB - The aim of this study was to analyze the required absorbed doses to detectable metastases (Dreq ) when using radionuclides with prostate specific membrane antigen (PSMA)-targeting radioligands to achieve a high probability for metastatic control. The Monte Carlo based analysis was performed for the clinically-used radionuclides yttrium-90, iodine-131, lutetium-177, and actinium-225, and the newly-proposed low-energy electron emitter terbium-161. It was demonstrated that metastatic formation rate highly influenced the metastatic distribution. Lower values generated few large detectable metastases, as in the case with oligo metastases, while high values generated a distribution of multiple small detectable metastases, as observed in patients with diffused visualized metastases. With equal number of detectable metastases, the total metastatic volume burden was 4–6 times higher in the oligo metastatic scenario compared to the diffusely visualized scenario. The Dreq was around 30% higher for the situations with 20 detectable metastases compared to one detectable metastasis. The Dreq for iodine-131 and yttrium-90 was high (920–3300 Gy). The Dreq for lutetium-177 was between 560 and 780 Gy and considerably lower Dreq were obtained for actinium-225 and terbium-161, with 240–330 Gy and 210–280 Gy, respectively. In conclusion, the simulations demonstrated that terbium-161 has the potential for being a more effective targeted radionuclide therapy for metastases using PSMA ligands.

UR - http://www.scopus.com/inward/record.url?scp=85104557288&partnerID=8YFLogxK

U2 - 10.3390/cancers13092011

DO - 10.3390/cancers13092011

M3 - Article

AN - SCOPUS:85104557288

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 9

M1 - 2011

ER -